| Description |
The commercial interest in discovering, developing, and marketing cancer therapeutics has increased due to an aging population, earlier detection and intervention, and the emergence of targeted therapies. However, there are many market specific issues that must be considered in building a cancer portfolio. Early cancer drugs with novel mechanisms often show pre-clinical promise, but carry high risk profiles. Risk can potentially be reduced by developing or in-licensing me-too compounds with proven mechanisms and large market sizes. However, there is still the regulatory risk and the challenge of commercialization in a crowded marketplace. The emergence of targeted cancer therapy and personalized medicine may initially reduce the market size for a drug and challenge the traditional economics of drug development.
To specifically address the current needs and emerging strategic issues in portfolio planning for oncology drugs, the Institute for International Research presents Building a Balanced Cancer Portfolio. The mission of the conference is to provide attendees with insight into the framework behind portfolio management, business development, and licensing decisions for cancer therapeutics.
Day One provides an overview of the oncology deals completed over the last five years and examines the role of licensing in oncology planning. The strategic and business implications of the developing therapeutics alongside diagnostics are presented. Risk management tools for optimizing drug development and maximizing commercial success are discussed. The potential (and pitfalls) inlicensing novel drug classes and mechanisms are also examined. Finally, the conference explores regulatory strategies of accelerating development and reviews regulatory due diligence considerations for your acquisition candidate.
Day Two begins with a presentation on how to best allocate limited resources for a portfolio. An evaluation of the risks of in-licensing early stage cancer drugs are presented alongside the risks of commercializing a portfolio of me-too drugs. The conference continues with a discussion of the potential of targeted therapy to increase the sales of cancer drugs already in your portfolio. New uses for approved cancer drugs and new combinations are examined as ways to fully realize value of your existing portfolio. As a smaller company, understand the scientific due diligence process at big pharma and why things seem to take so long. Finally, review the process by which a former platform company can utilize strategic alliances to create value in cancer therapeutics
Uncertain about revenue forecasting for
Oncology projects?
Join our pre-conference workshop:
Forecasting and Valuation of Oncology Products
Paul Thonnard of the Global Forecasting Team at Eli Lilly facilitates this workshop. Improve the accuracy of your assessments by refining valuation and revenue forecasting models and addressing dynamics of disease and market.
Opportunity to Network
Meet with colleagues and competitors. Bring plenty of
business cards with you for our luncheons and
refreshment breaks.
|
|
